Spryte Medical

Spryte Medical is pioneering intravascular imaging for the neurovascular space with its nOCT platform, which offers >10x the resolution of current angiography systems to visualize vessel walls, pathology, and implanted devices. The company has achieved significant milestones, including FDA Breakthrough Device Designation, IDE approval for a pivotal US trial (INSYTE), and first-in-human publications in high-impact journals. Positioned at the intersection of medical devices and AI, Spryte aims to become a standard-of-care imaging tool for neurointerventionalists treating aneurysms, stroke, and intracranial atherosclerosis.

Proprietary AI-enabled neuro Optical Coherence Tomography (nOCT) platform, consisting of a miniaturized, steerable fiber-optic imaging probe, an optical engine, and an AI-powered console. It delivers high-resolution (micrometer-scale) intravascular imaging specifically designed for the tortuous neurovasculature.

Spryte has no direct competitors with an FDA-approved intravascular imaging device for the neurovasculature. Indirect competition comes from established but lower-resolution imaging modalities used in the angiography suite, such as digital subtraction angiography (DSA) and cone-beam CT. Potential future competitors include large cardiology-focused IV-OCT companies (e.g., Abbott, Boston Scientific) or neurovascular device giants (e.g., Medtronic, Stryker) that could attempt to adapt their technologies for the brain.